Sodium Iodide Symporter in the Fight Against Thyroid Cancer
2013; Future Medicine; Volume: 9; Issue: 11 Linguagem: Inglês
10.2217/fon.13.129
ISSN1744-8301
Autores Tópico(s)Neuroblastoma Research and Treatments
ResumoFuture OncologyVol. 9, No. 11 General Content - EditorialSodium iodide symporter in the fight against thyroid cancerTakahiko KogaiTakahiko KogaiDepartment of Infection Control & Clinical Laboratory Medicine, Dokkyo Medical University, 880 Kitakobayashi, Mibu, Tochigi Prefecture, 321-0293, Japan. Published Online:24 Oct 2013https://doi.org/10.2217/fon.13.129AboutSectionsView ArticleView Full TextPDF/EPUB ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareShare onFacebookTwitterLinkedInRedditEmail View articleKeywords: radioiodidesignal transduction inhibitorsodium iodide symporterthyroid cancerReferences1 Maxon HR, Smith HS. Radioiodine-131 in the diagnosis and treatment of metastatic well differentiated thyroid cancer. Endocrinol. Metab. Clin. North Am.19(3),685–718 (1990).Crossref, Medline, Google Scholar2 Kogai T, Taki K, Brent GA. Enhancement of sodium/iodide symporter expression in thyroid and breast cancer. Endocr. Relat. Cancer13(3),797–826 (2006).Crossref, Medline, CAS, Google Scholar3 Van Nostrand D. The benefits and risks of I-131 therapy in patients with well-differentiated thyroid cancer. Thyroid19(12),1381–1391 (2009).Crossref, Medline, CAS, Google Scholar4 Kogai T, Brent GA. The sodium iodide symporter (NIS): regulation and approaches to targeting for cancer therapeutics. Pharmacol. Ther.135(3),355–370 (2012).Crossref, Medline, CAS, Google Scholar5 Durante C, Haddy N, Baudin E et al. Long-term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma: benefits and limits of radioiodine therapy. J. Clin. Endocrinol. Metab.91(8),2892–2899 (2006).Crossref, Medline, CAS, Google Scholar6 Kogai T, Endo T, Saito T, Miyazaki A, Kawaguchi A, Onaya T. Regulation by thyroid-stimulating hormone of sodium/iodide symporter gene expression and protein levels in FRTL-5 cells. Endocrinology138(6),2227–2232 (1997).Crossref, Medline, CAS, Google Scholar7 Riedel C, Levy O, Carrasco N. Post-transcriptional regulation of the sodium/iodide symporter by thyrotropin. J. Biol. Chem.276(24),21458–21463 (2001).Crossref, Medline, CAS, Google Scholar8 Taki K, Kogai T, Kanamoto Y, Hershman JM, Brent GA. A thyroid-specific far-upstream enhancer in the human sodium/iodide symporter gene requires Pax-8 binding and cyclic adenosine 3´,5´-monophosphate response element-like sequence binding proteins for full activity and is differentially regulated in normal and thyroid cancer cells. Mol. Endocrinol.16(10),2266–2282 (2002).Crossref, Medline, CAS, Google Scholar9 Dohan O, De la Vieja A, Paroder V et al. The sodium/iodide symporter (NIS): characterization, regulation, and medical significance. Endocr. Rev.24(1),48–77 (2003).Crossref, Medline, CAS, Google Scholar10 Saito T, Endo T, Kawaguchi A et al. Increased expression of the sodium/iodide symporter in papillary thyroid carcinomas. J. Clin. Invest.101(7),1296–1300 (1998).Crossref, Medline, CAS, Google Scholar11 Dohan O, Baloch Z, Banrevi Z, Livolsi V, Carrasco N. Rapid communication: predominant intracellular overexpression of the Na+/I- symporter (NIS) in a large sampling of thyroid cancer cases. J. Clin. Endocrinol. Metab.86(6),2697–2700 (2001).Crossref, Medline, CAS, Google Scholar12 Smith VE, Read ML, Turnell AS et al. A novel mechanism of sodium iodide symporter repression in differentiated thyroid cancer. J. Cell Sci.122(Pt 18),3393–3402 (2009).Crossref, Medline, CAS, Google Scholar13 Read ML, Lewy GD, Fong JC et al. Proto-oncogene PBF/PTTG1IP regulates thyroid cell growth and represses radioiodide treatment. Cancer Res.71(19),6153–6164 (2011).Crossref, Medline, CAS, Google Scholar14 Smith V, Sharma N, Watkins R et al. Manipulation of PBF/PTTG1IP phosphorylation status; a potential new therapeutic strategy for improving radioiodine uptake in thyroid and other tumors. J. Clin. Endocrinol. Metab. doi:10.1210/jc.2012-3640 (2013) (Epub ahead of print).Google Scholar15 Fagin JA. Challenging dogma in thyroid cancer molecular genetics – role of RET/PTC and BRAF in tumor initiation. J. Clin. Endocrinol. Metab.89(9),4264–4266 (2004).Crossref, Medline, CAS, Google Scholar16 Chakravarty D, Santos E, Ryder M et al. Small-molecule MAPK inhibitors restore radioiodine incorporation in mouse thyroid cancers with conditional BRAF activation. J. Clin. Invest.121(12),4700–4711 (2011).Crossref, Medline, CAS, Google Scholar17 Ho AL, Grewal RK, Leboeuf R et al. Selumetinib-enhanced radioiodine uptake in advanced thyroid cancer. N. Engl. J. Med.368(7),623–632 (2013).Crossref, Medline, CAS, Google Scholar18 Bommarito A, Richiusa P, Carissimi E et al.BRAFV600E mutation, TIMP-1 upregulation, and NF-kappaB activation: closing the loop on the papillary thyroid cancer trilogy. Endocr. Relat. Cancer18(6),669–685 (2011).Crossref, Medline, CAS, Google Scholar19 Kogai T, Sajid-Crockett S, Newmarch LS, Liu YY, Brent GA. Phosphoinositide-3-kinase inhibition induces sodium/iodide symporter expression in rat thyroid cells and human papillary thyroid cancer cells. J. Endocrinol.199(2),243–252 (2008).Crossref, Medline, CAS, Google Scholar20 Hou P, Bojdani E, Xing M. Induction of thyroid gene expression and radioiodine uptake in thyroid cancer cells by targeting major signaling pathways. J. Clin. Endocrinol. Metab.95(2),820–828 (2010).Crossref, Medline, CAS, Google ScholarFiguresReferencesRelatedDetailsCited ByTargeting uptake transporters for cancer imaging and treatmentActa Pharmaceutica Sinica B, Vol. 10, No. 1 Vol. 9, No. 11 eToC Sign up Follow us on social media for the latest updates Metrics Downloaded 155 times History Published online 24 October 2013 Published in print November 2013 Information© Future Medicine LtdKeywordsradioiodidesignal transduction inhibitorsodium iodide symporterthyroid cancerAcknowledgementsThe author would like to thank G Brent for helpful discussions and advice.Financial & competing interests disclosureThe author has no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.No writing assistance was utilized in the production of this manuscript.PDF download
Referência(s)